garding associations of tau localization and density with clinical features of AD in vivo.
We performed a detailed clinical and trimodal imaging study, using fluorine 18- 
]PiB) PET scan, and structural magnetic resonance imaging (MRI), of 6 patients with biomarker evidence of AD pathologic conditions, 3 of whom have a typical amnesic AD syndrome, and 3 of whom have atypical clinical syndromes, including PCA, lvPPA, and CBS. We hypothesized that clinical phenotype of patients with typical and atypical AD will be associated with the topography of cortical tau but not amyloid pathologic conditions, as measured by [ 
Methods

Participants
This study was conducted from July 1, 2012, to July 30, 2015 . Six patients were recruited from the Massachusetts Frontotemporal Disorders Unit and Alzheimer Disease Research Center Early Onset Dementia Longitudinal Cohort. Each patient's diagnosis was made or confirmed by a behavioral neurologist (B.C.D.) after a comprehensive evaluation, as described previously. 10 Patients 1, 2, and 3 met diagnostic criteria for typical amnesic multidomain probable AD dementia with executive dysfunction. Patients 1 and 2 also exhibited mild visual constructional impairment. Medial temporal lobe and lateral temporoparietal atrophy was present on visual inspection of MRI results for patients 1, 2, and 3. 11 Patient 4 met criteria for PCA, with an initial and progressive cortical visual disturbance (Balint syndrome on results of neurologic examination) in the absence of memory loss, along with alexia, agraphia, and limb apraxia; right lateralized biparietal atrophy was present on visual inspection of MRI results. 12, 13 Patient 5 met criteria for lvPPA, with variably fluent speech and impairments in lexical retrieval and phonologic errors in spontaneous speech and on confrontation naming, impaired repetition of phrases, and spared single word comprehension, motor speech, and grammar, with spared episodic memory and visual function; left lateralized posterolateral temporal and inferior parietal atrophy was present on visual inspection of MRI results. 14 Patient 6 met criteria for CBS, with mild left limb rigidity, dystonia, and myoclonus, moderate limb apraxia greater on the left side than right side, a moderate bilateral cortical sensory deficit greater on the left side than right side, and alien limb of the left arm, whereby the left arm moved without voluntary control; right-lateralized perirolandic atrophy was present on visual inspection of MRI results. 15 The 19 where regional time-activity curves were used to compute regional DVRs for each ROI using the Logan graphical method applied to data from 40 to 60 minutes after injection. 20 Data from the PET imaging were not partial volume corrected.
Neuroimaging Data Analysis
To visually compare the distribution of cortical thickness with that of PET imaging tracer uptake, we created individual maps for atrophy as well as bilateral medial prefrontal cortex for all 3 patients, where little to no cortical atrophy had been observed, and in the posteromedial cortex, the spatial pattern commonly seen in patients with AD dementia. 24 In the patients with atypical clinical AD syndromes, high [ A similar pattern was seen for the 3 patients with atypical AD clinical syndromes. For each patient, [ 18 F]AV-1451 SUVR within a given ROI was strongly correlated with the cortical thickness z score (patient 4, r = -0.51; P < .001; patient 5, r = -0.63; P < .001; and patient 6, r = -0.70; P < .001), whereas [ 11 C]PiB tracer uptake was not associated with cortical thickness (patient 4, r = -0.02; P = .89; patient 5, r = 0.10; P = .44; and patient 6, r = 0.06; P = .64). These associations are illustrated in Figure 4 .
Discussion
The first use of the ligand now known as [
18 F]AV-1451 in patients with AD was reported in 2013. 25 The selectivity of this ligand for hyperphosphorylated tau was recently confirmed. 26 In addition, a study was completed in which an elevated [
18 F]AV-1451 signal in mild cognitive impairment likely owing to AD and AD dementia showed a topography largely consistent with Braak staging and its magnitude correlated with level of clinical impairment. 18 In this study, we provide further evidence that clinical phenotype of individual patients with AD is associated with the localization of tau pathologic findings in vivo as measured by [ shown by previous neuropathologic reports demonstrating a strong association between distribution and severity of tau pathologic findings and clinical symptoms in patients with typical and atypical AD, 4 and is also consistent with several recent case reports and one larger study demonstrating a similar pattern of findings. [27] [28] [29] [30] The ability of [
18 F]AV-1451 to localize tau pathologic findings at the individual patient level in a manner concordant with symptoms supports its clinical validity as a new in vivo imaging biomarker in AD. Although cerebrospinal fluid tau has been validated as a specific biomarker of clinically diagnosed and autopsy-confirmed AD, 31 it cannot provide information about the localization of tau pathologic findings. Our ability to test many hypotheses regarding the association of tau to neurologic symptoms in vivo requires information about its localization. Although results of MRI and [ 
27-30
Studies of the pathologic basis of measures of regional atrophy in AD as seen on results of MRI have found associations with neurofibrillary pathologic findings. 33, 35 Previous in vivo biomarker investigations in prodromal and mild AD dementia have demonstrated stronger associations between cerebrospinal fluid tau and atrophy in selected temporal cortical regions 36 and in widely distributed cortical regions where thinning is associated with AD. 37 The data presented in Figures 3 and 
Limitations
One limitation of this study is the small number of patients. We did not have a large enough sample size to examine the quantitative association between regional [
18 F]AV-1451 tracer binding and cognitive measures. This outcome is an aim of a follow-up study. However, given the robustly consistent associations between the measures across all 6 patients with diverse clinical presentations, we are confident that this set of results will be readily replicable in larger samples. Furthermore, the consistency of these results with those of neuropathologic studies provides additional assurance that sample size is not likely a major limitation. Nevertheless, at this point, 
